Bluebird bio Inc (BLUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bluebird bio Inc (BLUE) has a cash flow conversion efficiency ratio of 0.751x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.44 Million) by net assets ($-57.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Bluebird bio Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Bluebird bio Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Bluebird bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bluebird bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluebird bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ConvaTec Group PLC
LSE:CTEC
|
0.086x |
|
Quartiers Properties AB
ST:QUART
|
0.048x |
|
Nh Prime Reit Co Ltd
KO:338100
|
N/A |
|
Space Com
TA:SCC
|
-0.893x |
|
Lay Hong Bhd
KLSE:9385
|
0.094x |
|
VHM Ltd
AU:VHM
|
-0.041x |
|
Scilex Holding Company
NASDAQ:SCLX
|
0.004x |
|
Wooshin System
KO:017370
|
-0.050x |
Annual Cash Flow Conversion Efficiency for Bluebird bio Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Bluebird bio Inc from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see Bluebird bio Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-31.53 Million | $-260.02 Million | 8.246x | +782.46% |
| 2023-12-31 | $194.54 Million | $-235.05 Million | -1.208x | +32.79% |
| 2022-12-31 | $196.34 Million | $-352.95 Million | -1.798x | -5.85% |
| 2021-12-31 | $374.28 Million | $-635.64 Million | -1.698x | -389.27% |
| 2020-12-31 | $1.36 Billion | $-470.35 Million | -0.347x | +20.97% |
| 2019-12-31 | $1.28 Billion | $-564.38 Million | -0.439x | -100.26% |
| 2018-12-31 | $1.89 Billion | $-413.43 Million | -0.219x | -26.91% |
| 2017-12-31 | $1.62 Billion | $-280.55 Million | -0.173x | +20.77% |
| 2016-12-31 | $869.44 Million | $-189.65 Million | -0.218x | -88.48% |
| 2015-12-31 | $850.50 Million | $-98.43 Million | -0.116x | +4.76% |
| 2014-12-31 | $491.26 Million | $-59.69 Million | -0.122x | -142.41% |
| 2013-12-31 | $151.67 Million | $43.45 Million | 0.286x | -24.11% |
| 2012-12-31 | $-55.75 Million | $-21.04 Million | 0.377x | +72.13% |
| 2011-12-31 | $-55.71 Million | $-12.22 Million | 0.219x | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more